Liposomes: An Emerging Approach for the Treatment of Cancer

Author(s): Keerti Mishra, Akhlesh K. Jain*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 20 , 2021

Become EABM
Become Reviewer
Call for Editor


Background: Conventional drug delivery agents for a life-threatening disease, i.e., cancer, lack specificity towards cancer cells, producing a greater degree of side effects in the normal cells with a poor therapeutic index. These toxic side effects often limit dose escalation of anti-cancer drugs, leading to incomplete tumor suppression/ cancer eradication, early disease relapse, and ultimately, the development of drug resistance. Accordingly, targeting the tumor vasculatures is essential for the treatment of cancer.

Objective: To search and describe a safer drug delivery carrier for the treatment of cancer with reduced systemic toxicities.

Method: Data were collected from Medline, PubMed, Google Scholar, Science Direct using the following keywords: ‘liposomes’, ‘nanocarriers’, ‘targeted drug delivery’, ‘ligands’, ‘liposome for anti-cancerous drugs’, ‘treatment for cancer’ and ‘receptor targeting.’

Results: Liposomes have provided a safe platform for the targeted delivery of encapsulated anti-cancer drugs for the treatment of cancer, which results in the reduction of the cytotoxic side effects of anti-cancer drugs on normal cells.

Conclusion: Liposomal targeting is a better emerging approach as an advanced drug delivery carrier with targeting ligands for anti-cancer agents.

Keywords: Cancer, anti-cancer drugs, nanocarriers, drug delivery, liposomes, ligands, targeted therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 06 April, 2021
Page: [2398 - 2414]
Pages: 17
DOI: 10.2174/1381612827666210406141449
Price: $65

Article Metrics

PDF: 47